(Q63833016)
Statements
Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated Over a Period of 3 Years or 5 Years if Applicable, in Comparison With a Historic Cohort of Non-treated Children With Hypochondroplasia (English)
0 references
21 March 2006
0 references
17 January 2017
0 references
19
0 references
3 year
0 references